Navigation Links
ResMed Takes New Action to Enforce Patents
Date:7/22/2013

SAN DIEGO, July 22, 2013 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions, has filed a new legal action in the International Trade Commission (ITC) and an amended complaint in U.S. federal court to stop the infringement of ResMed patents.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed filed the action against Chinese medical device manufacturer BMC Medical Co., Ltd. (BMC) and its U.S. sales subsidiary, 3B Products, LLC, (3B) asserting patent infringement by:

  • The RESmart CPAP and RESmart Auto CPAP devices
  • The Willow nasal pillows patient interface and the iVolve nasal mask.
  • ResMed is asking the ITC to stop the importation and sales of these products in the United States. ResMed has also amended a pending action in the U.S. federal court to assert additional patents that BMC and 3B are infringing.  ResMed is asking the court to stop the infringement and to award damages against BMC and 3B. 

    "ResMed built its market leadership by investing in superior technology for sleep-disordered breathing therapy," said ResMed global general counsel and chief administrative officer David Pendarvis.  "The proprietary technology in our masks and flow generators makes them comfortable and user-friendly, and our data management and reporting tools create a faster, smoother path to patient engagement. We will continue to defend our proprietary technology by enforcing our patents against those who unfairly copy our products."

    About ResMed:
    ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.Contacts:For News MediaFor the Investor CommunityGretchen GriswoldConstance BienfaitDirector, Global Corporate CommunicationsDirector, Investor RelationsO: 858-836-6789O: 858-836-5971news@resmed.comconstance.bienfait@resmed.com 


    '/>"/>
    SOURCE ResMed Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ResMed Succeeds in Patent Fight Against APEX
    2. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
    3. FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and Positive Study Outcomes - Research Report on Boston Scientific, Zimmer, St. Jude, ResMed, and GenMark
    4. ResMed Takes Action to Enforce Patents Against BMC and 3B
    5. ResMed Launches SleepSeeker Online Tool to Increase Patient Engagement in Therapy for Sleep-Disordered Breathing
    6. The University of Sydney and ResMed partner to accelerate research in sleep-disordered breathing and biomedical engineering
    7. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2013
    8. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
    9. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
    10. ResMed Takes Action to Enforce Patents
    11. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
    (Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
    (Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
    Breaking Medicine Technology:
    (Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
    (Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
    (Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
    (Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
    (Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
    Breaking Medicine News(10 mins):